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Promoter hypermethylation mediated by DNA methyltransferases (DNMTs) is the main reason for epigenetic inactivation of
tumor suppressor genes (TSGs). Previous studies showed that DNMT1 and DNMT3B play an important role in CpG island
methylation in tumorigenesis. Little is known about the role of DNMT3A in this process, especially in hepatocellular carcinoma
(HCC). In the present study, increased DNMT3A expression in 3 out of 6 HCC cell lines and 16/25 (64%) HCC tissues implied
that DNMT3A is involved in hepatocellular carcinogenesis. Depletion of DNMT3A in HCC cell line SMMC-7721 inhibited cell
proliferation and decreased the colony formation (about 65%). Microarray data revealed that 153 genes were upregulated in
DNMT3A knockdown cells and that almost 71% (109/153) of them contain CpG islands in their 5  region. 13 of them including
PTEN, a crucial tumor suppressor gene in HCC, are genes involved in cell cycle and cell proliferation. Demethylation of PTEN
promoter was observed in DNMT3A-depleted cells implying that DNMT3A silenced PTEN via DNA methylation. These results
provide insights into the mechanisms of DNMT3A to regulate TSGs by an epigenetic approach in HCC.
1.Introduction
Aberrant methylation of tumor suppressor genes (TSGs),
which result in their silencing, is a common phenomenon
in tumorigenesis [1, 2]. DNA methyltransferases (DNMTs)
DNMT1, DNMT3A, and DNMT3B have been identiﬁed
as functional DNA methylation enzymes in eukaryotic
cells [3, 4]. DNMT3A and DNMT3B function as de novo
methyltransferases that are responsible for de novo methy-
lation, whereas DNMT1 functions as a maintenance enzyme
for retaining methylation patterns. CpG islands residing
within the promoter or the 5  end of genes are normally
unmethylated in normal cells, and abnormal methylation
of these CpG islands can eﬃciently repress transcription
of the associated gene [5]. Silencing of TSGs by epigenetic
alterations at promoter CpG islands is a common event
found in many types of human cancers, including hepato-
cellular carcinoma (HCC). Overexpression of DNMTs has
been reported in numerous studies on various malignancies
includingprostate,colorectal,andbreasttumors.Theseﬁnd-
ings suggest that DNMTs may contribute to tumorigenesis
throughepigeneticsilencingofgenes[6–11].Thetargetingof
individual DNMTs to a gene is believed to play a critical role
in determining its state of methylation. RNA interference-
mediated knockdown or speciﬁc inhibition by antisense
oligo-nucleotides of DNMT1 resulted in the reduction of
promotermethylationinTSGs,suchasRASSF1A,p16INK4a,
andCDH1[12,13].SatelliteDNAisthetargetofmethylation
by DNMT3B. Interestingly, DNMT3B is also responsible
for immunodeﬁciency, centromere instability, and facial
anomalies(ICF)syndrome[14,15].Moreover,recentstudies
have shown that DNMT3B expression contributes to a
CpG island methylator phenotype and that it epigenetically
silences CXCL12 [16], RECK [17], and RASSF1A [18]
through DNMT3B-mediated promoter methylation.
The function of DNMT3A is obscure and has not
been associated with disease. DNMT3A is ubiquitously
overexpressed in various types of tumors [19–22] implying2 Journal of Biomedicine and Biotechnology
that it may be involved in and play an important role
in tumorigenesis. However, very little is known about
DNMT3A’s ability to regulate gene expression, especially in
regulating tumor suppressor genes. Recent results showed
that DNMT3A expression mediates the repression of SFRP5
[23]a n dplakoglobin transcription [24] by direct hyper-
methylation of their promoter, indicating that DNMT3A’s
methylation activities are gene speciﬁc. However, the target
genes of DNMT3A remain unknown. In this study, we
attemptedtoidentifytumor-relatedgenesthatarepotentially
regulated by DNMT3A and further discuss the prospect
of gene expression regulation by DNMT3A. In this report,
we also investigated the role of DNMT3A in the aberrant
methylation and inactivation of genes in human tumor cells
as well as its role in the maintenance of the transformed
phenotype.
2.MaterialsandMethods
2.1. HCC Cell Lines
2.1.1. HCC Cell Lines and Tissue Samples from Patients.
HCC-derived cell lines (QGY-7701, Bel-7402, Bel-7404, Bel-
7405, SMMC-7721) para-carcinoma cell line QSG-7701, and
immortalized human normal hepatocyte cell line HL-7702
were obtained from TCC Cell Bank (Shanghai, China) and
cultured with standard medium: RPMI 1640 (GIBCO-BRL,
Gaithersburg, MD) supplemented with 10% fetal bovine
serum (GIBCO-BRL) in a 5% CO2 humidiﬁed chamber at
37
◦C. Tumor tissues and adjacent noncancerous tissue from
25 HCCs were obtained from the First Aﬃliated Hospital,
Nanjing Medical University, from May 2008 to Decem-
ber 2009. All patients were conﬁrmed histopathologically
and samples were obtained with informed consent from
patients.
2.2. DNMT3A RNA Interference Constructs and Transfec-
tion. Three candidate siRNAs against human DNMT3A
were designed for targeting diﬀerent coding regions of
the DNMT3A isoforms (Genbank No. NM 175629.1,
NM 153759.2, NM 022552.3). Synthesized 64nt siRNA tem-
plate oligonucleotides were constructed into BglII and
HindIII (TAKARA) sites of pSUPER-EGFP (gift from Pro-
fessor Dianqing Wu at UCHC, USA), which has a green
ﬂuorescent protein marker and resistance to the G418, and
named as pMT3A. The scramble sequences of DNMT3A
s i R N Aw e r eu s e da sc o n tr o la n di n s e rt e di n t op S U P E R - E G F P
to form sMT3A. SMMC-7721 cells were transfected with
recombinant plasmids using Lipofectamine 2000 according
to the manufacturer’s protocols (Invitrogen Corp., Carlsbad,
CA) and were selected with medium containing 200mg/mL
G418 (Gibco, Grand Island, NY) for 2 months after the
initial transfection. The cells stably harboring the targeting
vector were monitored with green ﬂuorescent protein (GFP)
expression. SMMC-7721 cells were transfected with pMT3A
and labeled as 7721–pMT3A cell lines; these were transfected
with sMT3A and were designated as 7721–sMT3A cell lines
or control.
2.3. Western Blot Analysis. Cells (5 × 106)w e r eh a r v e s t e d
and the total proteins were prepared. Cell precipitate was
resuspedded in 200uli c e - c o l dl y s i sb u ﬀer (10mmol/L
Tris-Hcl (pH 8.0), containing 150mmol/L NaCl, 1mmol/L
phenylmethylsulfonyl ﬂuoride, and 1% Triton X-100). An
equal amount of cellular proteins was loaded on 7%
polyacrylamide gels (PAGE) in a 1×SDS-PAGE buﬀer (1g/L
SDS, 3g/L Tris-base, and 14.4g/L glycine). Proteins were
transferred to a polyvinylpyrrolidine diﬂuoride membrane
electrophoretically and incubated overnight at 4 in block
buﬀer (5% nonfat milk in Tris-Base Tween-20 (TBST).
Membranes were incubated for 1 hour at room temperature
with DNMT3A-speciﬁc monoclonal antibodies (1:5000,
Imagenex) followed by six ﬁve-minute washes with TBST.
After washing, the membrane was incubated with anti-
mouse horseradish peroxidase-conjugated secondary anti-
bodies (1:80000, Sigma), and the immune complexes
were detected with enhanced chemiluminescence (Pierce).
The membranes were probed with an antiactin antibody
(Biomedical Technologies, Stoughton, MA) to conﬁrm equal
loading of each protein samples. β-actin protein levels were
used as a control to ensure equal protein loading (β-actin,
1:8000, Sigma). Each experiment was repeated at least 3
times. The intensity ratios of the 2 bands from the same
sample were determined and calculated by Gel-Pro Analyzer
3.0.
2.4. Microarray Hybridizations and Induced Genes Analysis.
Aﬀymetrix Human Genome U133A 2.0 Array (Aﬀymetrix,
Santa Clara, CA), encompassing 18,400 transcripts and
variants, including 14,500 well-characterized human genes
on one array was processed. Microarray hybridization was
performed in the SBC (Shanghai, China) using standard
aﬀymetrix procedures. Raw microarray data were acquired
using GCOS1.2 software of aﬀymetrix. The data were
preprocessed using robust multiarray analysis (RMA) with
a log base 2 (log2) transformation. Genes identiﬁed as
diﬀerentially expressed genes, which is exhibiting, upreg-
ulated more than 2-fold to the control. Gene ontol-
ogy of the diﬀerentially expressed genes was performed
through the GO Mining Tool (http://www.aﬀymetrix.com/
analysis/query/go analysis.aﬀx). The potential promoter
regions spanning 2000bp upstream and 5’UTR around
the transcription start site of 153 upregulated genes.
Subsequently, CpG islands were identiﬁed within the
core promoter region by CpG Island Searcher program
(http://www.methdb.de/) in DNA Methylation Database
(http://www.uscnorris.com/cpgisland2).
2.5. Reverse Transcription Polymerase Chain Reaction (RT-
PCR) and Real-Time Quantitative RT-PCR (qPCR) Analysis.
Total RNA was isolated using TRIzol reagent (Invitrogen,
NY). cDNA was synthesized from 1μg of total RNA using
Oligo(dT)18 as primers and reverse transcriptase follow-
ing reverse-transcribed with Reverse Transcription System
(Promega,) according to the kit’s instructions. The expres-
sion levels of diﬀerentially expressed genes of microarray
after DNMT3A RNAi were quantiﬁed using qRT-PCR anal-
ysis. PCR reactions containing 10ng cDNA, SYBR greenJournal of Biomedicine and Biotechnology 3
(1:20,000 dilutions) were included in each reaction to allow
quantiﬁcation of RNA levels using the ABI 7300 detection
system (Applied Biosystems). To normalize the input load
of cDNA among samples, either β-actin was quantiﬁed
and used as an endogenous standard. The relative levels
of expression of each target genes among diﬀerent samples
were calculated accordingly (ABI PRISM 7300 Detection
System, USA). The conditions and primers designed for
detected genes were listed in Table 1. Each duplex PCR was
repeated with at least 3 diﬀerent cDNA preparations and 2
independent qPCR reactions for each cDNA.
2.6. Methylation-Speciﬁc PCR (MSP), Bisulﬁte Sequencing,
and Treatment of 5-aza-dC. Genomic DNA was extracted
according to standard method [25]. Bisulﬁte treatment was
performed by the Methylamp DNA Modiﬁcation Kit (Epi-
gentek) following the manufacturer’s instruction. Modiﬁed
DNA was ampliﬁed to determine the methylation status of
the promoter region of gene by MSP. The primer sequences
and PCR conditions for ampliﬁcation above were shown
in Table 2. PCR products for the bisulﬁte sequencing were
gel-puriﬁed, subcloned into a pEASY-T3 vector system
(TransGen Biotech). At least ten colonies were sequenced
to assess the degree of methylation in each CpG site. For
demethylation analysis, cells were plated and treated with
100μmol/L5-aza-dC(Sigma)forupto4days.ThetotalRNA
wasextractedfromexponentiallygrowingculturesonthe3rd
day after treatment.
2.7. Cell Proliferation and Colony Formation Assay. Cell
proliferation of transfected stable SMMC-7721 cells with
construct pMT3A and its control sMT3A were measured
by Cell Counting Kit-8 (CCK-8) (Dojindo Laboratories,
Kumamoto,Japan).Theabsorbanceat450nmwasmeasured
to represent the cell viability, which was measured to assess
the cell proliferation of those cell lines. All experiments were
independently repeated at least three times.
1 × 103 cells were suspended in 1.5ml of 0.3%-melted
agarinRPMI1640medium(Invitrogen,Carlsbad,CA.USA)
with 5% FCS, and plated in a standard 6-well cell culture
plate containing a solidiﬁed layer of 3ml 0.6% agarose gel
in the same medium. After 14 days of incubation at 37
◦Ci n
5% CO2, colony growth in soft agar was assayed by visually
counting the colonies. All evaluations were performed in
a blinded manner. The experiments were independently
performed three times.
2.8. Statistical Analysis. Data were presented as means ±
standard error (SE). Data were analyzed using Graphpad
Prism 5 software (GraphPad Software, San Diego, CA).
Mean diﬀerencewasdeterminedbyStudentt-tests.Statistical
signiﬁcant diﬀerences were deﬁned as P<. 05. Standard
statistical tests were performed using SPSS (version 13.0).
3. Results
3.1. Increased Expression of DNMT3A in HCC Cell Lines and
HCC Tissues. The expression level of DNMT3A was mea-
sured in HCC cell lines by western blot and was normalized
to β-actin. There was lower expressed DNMT3A in human
normal liver cells (HL-7702) and diﬀerentially expressed
in HCC cell lines (Figure 1(a)). Increased expression of
DNMT3A was found in 3 out of 6 HCC cell lines, especially
in SMMC-7721 and BEL-7402. Speciﬁcally, there was a 6.1-
and 5.8-fold increase in DNMT3A expression in SMMC-
7721 and BEL-7402, compared to HL-7702, respectively. The
mRNA expression level of the DNMT3A was detected by
qPCR in tumor tissues and noncancerous liver tissues from
25 HCC patients. Increased expression of DNMT3A was
detected in 16 out of 25 cases (64%) of HCCs (Figure 1(b)).
These data suggested that DNMT3A may play a role in the
progression of HCC tumorigenesis, and this ﬁnding needs to
be conﬁrmed by a larger study.
3.2. DNMT3A siRNA Construct Suppresses DNMT3A Specif-
ically and Stably in HCC Cell Line. Knockdown of tran-
scripts using siRNA is a powerful tool for studying gene
function. We designed three target siRNAs (Figure 2(a)),
w h i c hc a ns u p p r e s sa l lo ft h ed i ﬀerent DNMT3A transcripts,
and one nonspeciﬁc scramble siRNA, which was used as
control (see Table 1 in Supplementary Material available
online at doi:10.1155/2010/737535). The candidate siRNA-
2e ﬀectively suppressed DNMT3A expression in levels of
protein (P = .001) and encoding mRNA (P = .011) (Figures
2(b), 2(c), 2(d)). No signiﬁcant inhibition on DNMT1 and
DNMT3B was detected in DNMT3A RNAi treatment cells
(Figure 2(d)). Expression of endogenous β-actin was used
as a control to normalize the expression level of DNMT1,
DNMT3A,a n dDNMT3B.
3.3. Depletion of DNMT3A Inhibits Cell Proliferation and
Colony Formation in SMMC-7721 Cells. To explore the
functional consequences of DNMT3A depletion in HCC,
we evaluated the role of DNMT3A-speciﬁc siRNA treatment
on cell proliferation and colony formation in HCC cells.
Transfected clones were picked up and expanded for an
additional 2 months and analyzed for DNMT3A in protein
levels.DNMT3AexpressionwasstablysuppressedinSMMC-
7721 (Figure 3(a)). Compared to control 7721-sMT3A cells,
7721-pMT3A formed signiﬁcantly fewer colonies (about
65%) in soft agar assay (Figure 3(b)) and with lower cell
proliferation ability in CCK-8 cell assay (Figure 3(c)).
3.4. Gene Expression Proﬁling Induced by DNMT3A Knock-
down. Toelucidate the eﬀectsofincreased DNMT3Aexpres-
sion in HCC tumorigenesis, Aﬀymetrix HG U133A oligonu-
cleotide microarray was used to evaluate induced gene
expression proﬁling in DNMT3A depletion cells compared
with control. The data revealed that 153 genes were upreg-
ulated in DNMT3A knockdown cell (Supplementary Table
2). These genes were categorized to numerous biological
processes by using the GO Mining Tool [26]. All genes were
combined into 17 superordinate categories (Figure 4). Three
categories contained the largest number of aﬀected genes:
molecular transport (26 genes), transcription regulation (14
genes), and cell cycle (13 genes). Since a CpG island (CGI)
near the transcription initiation site is usually important4 Journal of Biomedicine and Biotechnology
Table 1: Primers sequences and related amplicons for quantitative real-time RT-PCR or RT-PCR.
Genes Primers (5 –3 ) Anneal temperature (
◦C) Amplicon (bp)
β-actin Forward: AAAGACCTGTACGCCAACAC 61 220
Reverse: GTCATACTCCTGCTTGCTGAT
DNMT3A Forward: TATTGATGAGCGCACAAGAGAGC 65 111
Reverse: GGGTGTTCCAGGGTAACATTGAG
DNMT3B Forward: GACTTGGTGATTGGCGGAA 64 271
Reverse: GGCCCTGTGAGCAGCAGA
DNMT1 Forward: CCGAGTTGGTGATGGTGTGTAC 61 325
Reverse: AGGTTGATGTCTGCGTGGTAGC
PTEN-q Forward: CCGTTACCTGTGTGTGGTGATATC 60 100
Reverse: AATGTATTTACCCAAAAGTGAAACATT
Table 2: Primers sequences for MSP and bisulﬁte sequencing analysis.
Gene Primers (5 –3 ) Anneal temperature (
◦C)
PTEN-M
a Forward: TTTTTTTTCGGTTTTTCGAGGC 59
Reverse: CAATCGCGTCCCAACGCCG
PTEN-UM
b Forward: TTTTGAGGTGTTTGGGTTTTTGGT 59
Reverse: ACACAATCACATCCCAACACCA
PTEN-BGS
c Forward: ATTGGGTATGTTTAGTAGAGTT 60
Reverse: CAACTCTCAAACTTCCATCATA
a: Methylated primer sequences used for MSP. b: Unmethylated primer sequences used for MSP. c: Primer sequences used for bisulﬁte genomic sequencing.
D
N
M
T
3
A
e
x
p
r
e
s
s
i
o
n
l
e
v
e
l
0
2.5
5
7.5
H
L
-
7
7
0
2
Q
S
G
-
7
7
0
1
Q
G
Y
-
7
7
0
1
B
E
L
-
7
4
0
2
B
E
L
-
7
4
0
4
B
E
L
-
7
4
0
5
S
M
M
C
-
7
7
2
1
H
L
-
7
7
0
2
Q
S
G
-
7
7
0
1
Q
G
Y
-
7
7
0
1
B
E
L
-
7
4
0
2
B
E
L
-
7
4
0
4
B
E
L
-
7
4
0
5
S
M
M
C
-
7
7
2
1
DNMT3A
β-actin
(a)
C
a
s
e
s
0
10
20
Groups of DNMT3A expression level
T>P T= PT < P
T = tumor
P = para-tumor
(b)
Figure 1: DNMT3A expression is analyzed in HCC cell lines, HCC tumor tissue, and adjacent nontumor samples. (a) DNMT3A protein
expression level was detected in HCC cell lines by western blot. Upper panel, DNMT3A was examined by western blot in HCC cell lines.
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Pro Analyzer 3.0. DNMT3A was increased more in 3 HCC cell lines than in immortalized normal liver cell line HL-7702. (b) Real-time
quantitative RT-PCR analysis of DNMT3A expression in 25 pairs of HCC specimens and adjacent noncancerous liver tissues, normalized to
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Figure 2: DNMT3A gene expression is inhibited by siRNA of DNMT3A in SMMC-7721 cells. (a) Schematic representation of DNMT3A
mRNA structure and siRNA positions is showed. (b) Western blot analysis eﬃciency of DNMT3A siRNA, β-actin was used as reference
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evaluated the aﬀect of DNMT3A-speciﬁc siRNA on other DNMTs expression. (d) Real-time quantitative RT-PCR conﬁrmed the eﬃciency
of DNMT3A-speciﬁc siRNA and the aﬀect on other DNMTs mRNA expression.
for gene repression by DNA methylation, we searched for
the presence of CGIs in each gene by using CpG Island
Searcher in the DNA Methylation Database, referring to
the criteria established by Takai and Jones [27]. We found
that almost 71% (109/153) of genes contain CpG islands
in their 5  region. This indicated that these genes might
be regulated by DNA methylation. In an eﬀort to provide
further experimental evidence that the gene expression6 Journal of Biomedicine and Biotechnology
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Figure 3: Depletion of DNMT3A suppressed HCC cell growth and colony formation ability. (a) Expression of DNMT3A was stably
suppressed in SMMC-7721. 7721-sMT3A, which is transfected with scramble vector sMT3A, 7721-pMT3A, which is transfected with
candidate DNMT3A siRNA constructs. (b) Colony formation of SMMC-7721 cells was inhibited when transfected with DNMT3A siRNA.
The scramble vector served as a control. The number of colonies was counted from three independent experiments. The histogram shows
the colony formation eﬃciency, where the numbers represent the average value of three independent experiments.(c) Cell growth curve of
SMMC-7721 cells treated with the DNMT3A siRNA. The cells transfected with the scramble vector served as control. The experiments were
repeated at least three times. The result represents the average value of triplicate wells +/- the standard deviation.
changes observed on arrays were valid, quantitative real-time
PCR was used to analyze several cancer-related genes and
conﬁrmed the data from the array.
3.5. Depletion of DNMT3A Induced PTEN via Demethy-
lation of CpG Sites in Its Promoter Region. In DNMT3A
depletion cells, tumor suppressor gene PTEN was activated
(Figure 5(a)). As 5-Aza-2 deoxycytidine, a demethylation
agent could restore PTEN expression (Figure 5(b)); we
supposed that activated PTEN in DNMT3A depletion cells
is maybe involved in demethylation. To explore whether the
repression of PTEN expression is due to DNA methylation;Journal of Biomedicine and Biotechnology 7
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Figure4:Superordinatecategoriesofbiologicalprocessesidentiﬁed
by gene ontology (GO) mapping in depletion DNMT3A HCC cell
lines. All genes induced by inhibiting DNMT3A were combined
into 17 superordinate categories. Three categories contained the
largestnumberofaﬀectedgenes:moleculartransport,transcription
regulation, and cell cycle.
we examined the status of methylation of its promoter in
DNMT3A depletion cells 7721-pMT3A and control by MSP
method. The result showed that restoring of the PTEN was
signiﬁcantly associated with its promoter demethylation in
the 7721-pMT3A cell line (Figure (5(c))). Subsequently, a
331bp (−1128/−798) fragment that contained part of the
PTEN promoter and its 5  untranslated region (5  UTR)
(Figure 5(d)) is chosen for further methyaltion analysis by
bisulﬁte sequencing. Ten individual colonies were sequenced
toidentifymethylatedcytosineresidues.Wefoundthatallsix
CpG sites were unmethylated in 7721-pMT3A. In contrast,
diﬀerent CpG sites (S1, S2, S4, or S6) were methylated in the
7721-sMT3A cell line. The results indicated that DNMT3A
knockdown changed the methylation status of certain CpG
sites within the 5  UTR and promoter of the PTEN gene.
These data suggested that PTEN expression is regulated in
a methylation-dependent manner and that PTEN may be
preferentially methylated by DNMT3A.
4. Discussion
HCC is a severe disease with a very poor prognosis and
is the fourth largest cause of cancer-related deaths world-
wide [26, 28]. DNA hypermethylation of tumor suppressor
genes is frequently observed in HCCs [25, 29–31]. The
process of aberrant DNA methylation is catalyzed by DNA
methyltransferases (DNMTs). Moreover, DNMTs expression
is increased during early tumorigenesis. In hepatocarcino-
genesis, increased expression of DNMTs mRNA is correlated
with a progressive increase in the number of methylated
genes from normal liver, chronic hepatitis/cirrhosis to HCC
[32].Onehypothesisisthatabnormalexpressionofthethree
functional DNMTs may be important in regulating tumor
suppressor gene expression during hepatocellular tumorige-
nesis. DNMT1 and DNMT3B were both shown to be impor-
tantforcancercellsurvivalandtumorigenesis[33].However,
the relationship between DNMT3A and tumorigenesis is
still uncertain. Previous studies suggested that DNMT3A is
developmentally regulated and was shown to be important
in establishing maternal imprints in mice [34, 35]. Recently,
researchers found that elevated DNMT3A activity promotes
polyposis in Apc (Min) mice [23] and that knockdown
of DNMT3A dramatically inhibits melanoma growth and
metastasis in mouse melanoma models [36]. Several studies
showed that increased expression of DNMT3A in HCC
implied that DNMT3A was involved in hepatocarcinogene-
sis. In order to evaluate the eﬀect of DNMT3A depletion,
weexaminedthecharacteristicsofSMMC-7721cellsinvitro,
using proliferation and colony-forming. The results showed
that cell proliferation and colony-forming ability did diﬀer
between the WT and DNMT3A-depleted SMMC-7721 cells.
DNMT3A depletion produced primarily antiproliferative
eﬀects. These results were observed in another HCC cell line
QSG-7701 (Supplementary). Microarray analysis revealed
that inhibition of DNMT3A induced expression of various
genes that are involved in cell cycle regulation, transcription
regulation, and signal transduction and are thus implicated
in the inhibition of HCC cell growth. Whether depletion
of DNMT3A is capable of inhibiting the growth of hepa-
tocellular carcinoma in vivo, mice malignant hepatocellular
carcinoma models should be established in the further study.
Our previous studies showed that depleting DNMT1
and DNMT3B induced expression of diﬀerent sets of TSGs
in HCC cell lines [37, 38]. Here, DNMT3A depletion
signiﬁcantly altered the expression of tumor-related genes
on the array. However, the regulation of these genes by
DNMT3A-mediated methylation or other epigenetic mech-
anisms is unknown. In addition to analyzing the inﬂuence of
DNMT3Adepletion on the broad changes in gene expression
by cDNA arrays, we sought to elucidate the potential mecha-
nism by which DNMT3A may regulate TSGs. To this end, we
beganananalysisofCGI sites containedwithinthepromoter
regions ofalteredgenesbyusingCpGIslandSearcher.Almost
71% (109/153) of induced genes contain CpG islands in
their 5  region, suggesting that DNA methylation plays an
important role in the regulation of gene expression by
DNMT3A. Compared with control, phosphatase and tensin
homolog (PTEN), a tumor suppressor gene in HCC, is
signiﬁcantly induced by DNMT3A knockdown. PTEN is
silenced by DNA methylation at high frequencies in HCC,
andpromotermethylationandsilencingofPTEN isreported
to be associated with HCC [39, 40]. One of the mechanisms
of PTEN inactivation is epigenetic silencing, which has
been reported in various tumors including hematologic
malignancies and some solid tumors [41–44]. In this study
we found that PTEN can be restored due to demethylation
of its promoter by demethylating agents in SMMC-7721
cells. PTEN is known for its essential role in regulating
the PI3K/AKT signaling pathway [45]. PTEN loss leads to
activation of AKT kinases, which contributes to cell survival,
growth,proliferation,andinvasion[46,47].Themethylation
of the PTEN promoter and its associated loss in activity is
observed in HCC. These results demonstrate that depletion
of DNMT3A aﬀects cell proliferation and that this eﬀect
may be a result of the reexpression of the formerly silenced
PTEN. In the present study, we found that DNMT3A may8 Journal of Biomedicine and Biotechnology
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Figure 5:RestoringofPTEN expressionbydepletionofDNMT3AinHCCcellsispartlyduetomethylationofitspromoter.(a)Quantitative-
PCR analysis of PTEN expression level in DNMT3A- d e p l e t e dc e l ll i n e .( b ) 5-Aza-2 deoxycytidine restored endogenous PTEN mRNA
expressioninSMMC-7721cells.(c)Methylatedstatusevaluationof PTEN promoterregiondeterminedbyMSP.ThepresenceofvisiblePCR
productinlanesmarked“U”indicatestheunmethylatedgene,whereasthepresenceofproductinlanesmarked“M”indicatesthemethylated
gene. (d) Bisulﬁte sequencing of the selected region of the PTEN promoter in DNMT3A-depleted SMMC-7721 cells. Top, sequences within
the fragment include 6 CpG sites (S1, S2, S3, S4, S5, S6). Bottom, the methylation pattern of 6 CpG sites in PTEN promoter region is shown.
T e nr a n d o mc l o n e sf r o mDNMT3A-depleted SMMC-7721cell line and control were sequenced to examine the methylated status. Open and
closed circles indicate unmethylated and methylated sites, respectively.
play a role in hepatocellular carcinogenesis by its role in
regulating the expression of some tumor suppressor genes
such as PTEN. However, it is necessary to further study
additional DNMT3A mechanisms of regulation of TSGs and
its function in tumorigenesis.
5. Conclusion
Our results provide evidence that DNMT3A depletion
signiﬁcantly inhibited cell growth and colony formation in
HCC cells. The most likely mechanism for this inhibition
of tumorigenesis includes the reactivation of epigenetically
silenced tumor suppressor genes, such as the PTEN gene.
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